Orexo Interim Report Q3 2022 |
November 03, 2022 | November 2022 Bond Updates |
UPPSALA, Sweden, Nov. 3, 2022 /PRNewswire/ -- Advancing the pipeline facilitating future growth Q3 2022 highlights Total net revenues of SEK 161.0 m (145.9) EBITDA of SEK -32.4 m (-47.4), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 14.3 m (-13.4) Net... |
View more at: https://www.prnewswire.com:443/news-releases/orexo-interim-report-q3-2022-301667251.html |
Related News |